U.S. Launch of Tryptyr Marks Breakthrough in Dry Eye Care

Credit: Alcon

Alcon has announced the U.S. launch of Tryptyr (acoltremon ophthalmic solution) 0.003%, a brand-new prescription treatment for dry eye disease, a condition that affects more than 30 million Americans. Approved by the U.S. Food and Drug Administration (FDA) in May 2025, Tryptyr is now available for doctors to prescribe nationwide.

Dry eye disease occurs when the eyes don’t make enough tears or when tears evaporate too quickly, leading to burning, irritation and blurred vision. Existing treatments often take weeks or months to work, and many patients feel their symptoms aren’t well controlled. In fact, only about 13% of patients in surveys said their dry eye was well managed.

Tryptyr is the first medication of its kind: a TRPM8 receptor agonist, a neuromodulator. Instead of simply trying to reduce inflammation or replace tears, it works by stimulating the eyes to produce more natural tears. Clinical studies showed that some patients experienced relief and improved tear production as early as Day 1.

“Tryptyr represents an important innovation — its fast onset and novel mechanism provide a new option to millions of dry eye patients,” said Paul Karpecki, O.D., a leading eye care specialist.

Alcon has also launched programs to help patients access Tryptyr. These include a First Fill Free trial program, copay support for eligible patients and resources for doctors to educate their patients about treatment.

Like any medication, Tryptyr has potential side effects. The most common one in clinical trials was mild eye pain or discomfort when putting in the drops, which affected about half of patients.

With modern lifestyles — especially increased screen time — driving a rise in dry eye disease across all ages, the launch of Tryptyr marks an important milestone. It offers patients and doctors a new, faster-acting option to manage symptoms and improve comfort.